title: Risk of ovarian cancer in relation to prediagnostic levels of C-peptide, insulin-like growth factor binding proteins-1 and -2 (USA, Sweden, Italy).
abstract: OBJECTIVE
  To investigate the association of prediagnostic circulating levels of C-peptide, as a marker of pancreatic insulin secretion, and IGF binding proteins -1 and -2, as indicators of the biologically active IGF-I concentration, with risk of developing ovarian cancer.
  
  
  METHODS
  The study was nested within three prospective cohorts in New York (USA), Umeå (Sweden) and Milan (Italy). Case subjects were 132 women with primary invasive epithelial ovarian cancer diagnosed at least one year after blood donation. For each case, two control subjects were selected, matching the case subject on cohort, menopausal status, age and date of recruitment (n = 263). Only women who did not use exogenous hormones at blood donation were included in the study.
  
  
  RESULTS
  Odds ratios and their 95% confidence intervals for risk of developing ovarian cancer over quartiles of peptides concentrations after adjustment for BMI and fasting were: 1.00, 0.66 (0.35-1.23), 0.96 (0.51-1.82) and 0.89 (0.44-1.81) for C-peptide; 1.00, 1.10 (0.58-2.09), 1.07 (0.55-2.04) and 0.79 (0.38-1.62) for IGFBP-1; and 1.00, 1.01 (0.54-1.89), 0.98 (0.51-1.88) and 0.87 (0.45-1.68) for IGFBP-2. In women who had ovarian cancer diagnosis before age 55 the ORs for the top tertiles of IGFBP-1 and IGFBP-2 were 0.51 (0.18-1.49) and 0.53 (0.18-1.54), respectively.
  
  
  CONCLUSIONS
  This study does not support an independent direct etiological role of C-peptide in ovarian cancer pathogenesis, but suggests a possible protective effect of circulating IGFBP-1 and -2 in women who develop ovarian cancer before age 55.
authors.affiliation: International Agency for Research on Cancer, Lyon, France.
authors.forename: Annekatrin
authors.initials: A
authors.lastname: Lukanova
authors.forename: Eva
authors.initials: E
authors.lastname: Lundin
authors.forename: Andrea
authors.initials: A
authors.lastname: Micheli
authors.forename: Arslan
authors.initials: A
authors.lastname: Akhmedkhanov
authors.forename: Sabina
authors.initials: S
authors.lastname: Rinaldi
authors.forename: Paola
authors.initials: P
authors.lastname: Muti
authors.forename: Per
authors.initials: P
authors.lastname: Lenner
authors.forename: Carine
authors.initials: C
authors.lastname: Biessy
authors.forename: Vittorio
authors.initials: V
authors.lastname: Krogh
authors.forename: Elio
authors.initials: E
authors.lastname: Riboli
authors.forename: Göran
authors.initials: G
authors.lastname: Hallmans
authors.forename: Franco
authors.initials: F
authors.lastname: Berrino
authors.forename: Anne
authors.initials: A
authors.lastname: Zeleniuch-Jacquotte
authors.forename: Paolo
authors.initials: P
authors.lastname: Toniolo
authors.forename: Rudolf
authors.initials: R
authors.lastname: Kaaks
mesh_terms: D000328:Adult; D000368:Aged; D002096:C-Peptide / Q000097:blood*; D015331:Cohort Studies; D005260:Female; D006801:Humans; D018970:Insulin-Like Growth Factor Binding Protein 1 / Q000097:blood*; D018971:Insulin-Like Growth Factor Binding Protein 2 / Q000097:blood*; D007558:Italy; D008875:Middle Aged; D016017:Odds Ratio; D010051:Ovarian Neoplasms / Q000453:epidemiology / Q000209:etiology* / Q000473:pathology; D012307:Risk Factors; D013548:Sweden / Q000453:epidemiology; D014481:United States / Q000453:epidemiology
chemical_list: D002096:C-Peptide; D018970:Insulin-Like Growth Factor Binding Protein 1; D018971:Insulin-Like Growth Factor Binding Protein 2